Potential biomarkers for clinical efficacy of CTLA‐4 inhibitors and chemotherapy include tumor mutation burden,23 T cell receptor coexpression signature, the lung immune prognostic index,24 and CTLA‐4 expression on tumors25; however, none have been definitively validated. The gene discussed is CTLA4; the disease is neoplasm.